James Sullivan

James Sullivan has a diverse work experience in the pharmaceutical industry spanning over several decades. Starting in 1997 at AstraZeneca as an Associate Director of Regulatory Affairs, they later joined Bristol-Myers Squibb in 2005 as the Director of Global Regulatory Sciences for the International division. James then moved to Takeda Pharmaceuticals, where they held roles as Director of International Regulatory Affairs in the Oncology Therapeutic Area and as the Boston Site Lead for the Emerging Markets Regulatory Group. After Takeda, Sullivan joined GE Healthcare as the Head of Regulatory Affairs for the US & Canada and as the Global Regulatory Lead. James then worked at Ipsen as the Senior Director of Neurosciences in the Global Regulatory Affairs division. Most recently, in 2021, they joined Ultragenyx Pharmaceutical Inc. as the Executive Director of Regulatory Strategy for Gene Therapy. Currently, since 2022, they hold the position of Vice President of Regulatory Affairs at Ardelyx, Inc.

James Sullivan completed their Bachelor of Science (BS) degree at the University of Massachusetts Dartmouth between 1993 and 1997. Following that, they pursued a Master of Science (MS) degree in Quality Assurance/Regulatory Affairs from the School of Pharmacy at Temple University, which they completed between 2000 and 2004.